Scleroderma Therapeutics Market Growth, Trends & Share | 2027
Market Overview
Scleroderma is a rare and chronic disease that affects around 2.5 million people across the world. The market for scleroderma therapeutics is expected to grow in the near future, owing to the factors, such as the rising prevalence of the disease and the focus of pharmaceutical companies, to come up with novel drugs.
- In the United Kingdom, around 19,000 people had been diagnosed with Scleroderma in the year 2018, as stated by Scleroderma & Raynaud’s UK. In the United Kingdom, Scleroderma & Raynaud’s UK is the only charity, which has been dedicated to improving the lives of people suffering from Scleroderma in the country. Studies have suggested that the prevalence of the disease is more in African Americans, and it is four to nine times higher in women than in men.
- Currently, there has been an improvement in the treatment of scleroderma toward managing complications and providing symptomatic relief. Disease-modifying treatment is widely being investigated for scleroderma, which has been aiming at inhibiting tissue fibrosis and vascular and immune system alterations, which are the three crucial components of disease pathogenesis.
- The upcoming therapies from pharmaceutical companies and future approvals of the same may boost the growth of the market studied.
Scope of the Report
Scleroderma is an autoimmune disease that affects the skin, blood vessels, muscles, and internal organs. The disease is usually caused due to an abnormal immune response. Therapies for this disease include immunosuppressive drugs and in some cases, glucocorticoids. Read Full Report
Comments
Post a Comment